Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2022-02-01 00:00:00 ET · period of report 2022-01-28 · accession 0001209191-22-005942 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-01 | 2022-01-28 | ELVN | Ballal Rahul D. | CEO | A - Grant | $0.00 | +131.4K | 137.0K | +2,343% | $0 |
| D | 2022-02-01 | 2022-01-28 | ELVN | Ballal Rahul D. | CEO | A - Grant | $0.00 | +131.4K | 131.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-28 | A | A | 131,400 | $0.00 | 137,009 | D | — | — | (F1) The shares underlying the restricted stock unit vest over four years, with 25% of the shares vesting in equal annual installments until the fourth anniversary of the grant date. |
| 2 | Derivative | Stock Option (right to buy) | 2022-01-28 | A | A | 131,400 | $0.00 | 131,400 | D | $1.38 · — to 2032-01-27 | 131,400 Common Stock | (F2) The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter. |